Camps Carlos, Caballero Cristina, Sirera Rafael, Blasco Ana, Cayuela Diego, Gil Mireia, Badía Xavier
Servicio de Oncología Médica, Hospital General Universitario de Valencia, Valencia, Spain.
Clin Transl Oncol. 2008 Feb;10(2):96-101. doi: 10.1007/s12094-008-0163-3.
Cancer is a high incidence disease, forcing healthcare systems to assign a significant amount of resources to its treatment. New developments have arisen recently: development of new agents that act at specific steps of cellular differentiation and proliferation and identification of predictive genetic markers which allow sub-groups of patients that will benefit from these agents, alone or in combination with chemotherapy, to be targeted. The majority of new drugs coming to the market combine greater clinical benefit and higher costs. Constraints on healthcare budgets worldwide make it necessary to rationalise the expense by prioritising allocation of available resources to the most efficient interventions, so that the best possible clinical result can be obtained at a reasonable cost and with the best quality of life for the patient. Economic evaluation studies represent the only tool available to scientifically determine the cost-effectiveness of new treatments and the budgetary impact of their introduction to the therapeutic arsenal available for the treatment of cancer.
癌症是一种高发病率疾病，这迫使医疗保健系统将大量资源用于其治疗。最近出现了一些新进展：开发作用于细胞分化和增殖特定步骤的新型药物，以及识别预测性基因标志物，从而能够针对那些单独或与化疗联合使用这些药物将获益的患者亚组。大多数上市的新药都兼具更大的临床益处和更高的成本。全球医疗保健预算的限制使得有必要通过将可用资源优先分配给最有效的干预措施来合理控制费用，以便能以合理成本获得尽可能好的临床结果，并为患者带来最佳生活质量。经济评估研究是唯一可用于科学确定新疗法的成本效益及其引入癌症治疗可用药物库所产生预算影响的工具。
